Paper · 39091908
Case report: Sequential treatment strategy for advanced basal cell carcinoma in Gorlin-Goltz syndrome: integration of vismodegib, radiotherapy, surgery, and high-intensity focused ultrasound.
Calik J and 4 others. Front Oncol, 2024. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Case report: Sequential treatment strategy for advanced basal cell carcinoma in Gorlin-Goltz syndrome: integration of vismodegib, radiotherapy, surgery, and high-intensity focused ultrasound. Papers, record 39091908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39091908
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Case report: Sequential treatment strategy for advanced basal cell carcinoma in Gorlin-Goltz syndrome: integration of vismodegib, radiotherapy, surgery, and high-intensity focused ultrasound.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,166,545 | Skin cancer: Etiology and management. | Pak J Pharm Sci | 2016 | https://conductscience.org/library/papers/27166545 | PubMed |
| 2 | 25,041,560 | Utility of radiotherapy for treatment of basal cell carcinoma: a review. | Br J Dermatol | 2014 | https://conductscience.org/library/papers/25041560 | PubMed |
| 3 | 31,990,414 | Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. | J Eur Acad Dermatol Venereol | 2020 | https://conductscience.org/library/papers/31990414 | PubMed |
| 4 | 37,992,360 | Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment. | Dermatol Pract Concept | 2023 | https://conductscience.org/library/papers/37992360 | PubMed |
| 5 | 29,062,253 | Gorlin-Goltz syndrome. | Turk Pediatri Ars | 2017 | https://conductscience.org/library/papers/29062253 | PubMed |
| 6 | 16,700,779 | Current modalities and new advances in the treatment of basal cell carcinoma. | Int J Dermatol | 2006 | https://conductscience.org/library/papers/16700779 | PubMed |
| 7 | 29,279,714 | Metastatic Basal Cell Carcinoma: A Rare Manifestation of a Common Disease. | Case Rep Med | 2017 | https://conductscience.org/library/papers/29279714 | PubMed |
| 8 | 38,892,988 | Pilot Study on High-Intensity Focused Ultrasound (HIFU) for Basal Cell Carcinoma: Effectiveness and Safety. | J Clin Med | 2024 | https://conductscience.org/library/papers/38892988 | PubMed |
| 9 | 23,888,252 | Targeted therapy for advanced Basal-cell carcinoma: vismodegib and beyond. | Dermatol Ther (Heidelb) | 2013 | https://conductscience.org/library/papers/23888252 | PubMed |
| 10 | 34,984,139 | Mohs Micrographic Surgery Versus Standard Excision for Basal Cell Carcinoma in the Head and Neck: Systematic Review and Meta-Analysis. | Cureus | 2021 | https://conductscience.org/library/papers/34984139 | PubMed |
1 to 10 of 38
See all 38 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,228,308 | High-Intensity Focused Ultrasound in Dermatology: A Review with Emphasis on Skin Cancer Management and Prevention. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228308 | PubMed |
| 40,299,236 | EZH2 inhibitor and Vismodegib synergistically inhibit the growth and metastasis of medulloblastoma. | Med Oncol | 2025 | https://conductscience.org/library/papers/40299236 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39091908
GET https://conductscience.org/api/papers/v1/39091908/references?page=2